Related references
Note: Only part of the references are listed.Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
Dimitrios Pectasides et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
R. Dummer et al.
ANNALS OF ONCOLOGY (2008)
Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone:: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
C. Garbe et al.
ANNALS OF ONCOLOGY (2008)
Survival end point reporting in randomized cancer clinical trials: A review of major journals
Simone Mathoulin-Pelissier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Management of melanoma: A European perspective
Alexander M. M. Eggermont et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2008)
Melanoma - Part 2: management
Christina Thirlwell et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Management of metastatic melanoma
Hussein A. Tawbi et al.
SEMINARS IN ONCOLOGY (2007)
Treatments for metastatic melanoma: Synthesis of evidence from randomized trials
Philip Lui et al.
CANCER TREATMENT REVIEWS (2007)
Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma
Stergios Moschos et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma
Malcolm S. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b
Zoya R. Yurkovetsky et al.
CLINICAL CANCER RESEARCH (2007)
Diagnosis and treatment of cutaneous melanoma: state of the art 2006
Claus Garbe et al.
MELANOMA RESEARCH (2007)
Prognostic implications of protein S-100 beta serum levels in the clinical outcome of high-risk melanoma patients
Josep Domingo-Domenech et al.
TUMOR BIOLOGY (2007)
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha:: A controlled, randomised multicentre trial
Rudolf Stadler et al.
ACTA ONCOLOGICA (2006)
Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease
Marko Lens
DERMATOLOGIC THERAPY (2006)
Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European cooperative adjuvant melanoma treatment study group
E Richtig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
AMM Eggermont et al.
LANCET (2005)
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
JM Kirkwood et al.
CLINICAL CANCER RESEARCH (2004)
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial:: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis
UR Kleeberg et al.
EUROPEAN JOURNAL OF CANCER (2004)
Medical progress - Management of cutaneous melanoma
H Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Interferon alpha as adjuvant postsurgical treatment of melanoma: A meta-analysis
D Pirard et al.
DERMATOLOGY (2004)
Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma
BW Hancock et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit?: A meta-analysis of the randomised trials
K Wheatley et al.
CANCER TREATMENT REVIEWS (2003)
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis
A Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
KL Kilbridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
N Cascinelli et al.
LANCET (2001)
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study
DA Cameron et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
